GILD

#88
Gilead Sciences, Inc. - Common Stock
135.5 2 USD
-0.04%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
134.58
136.48
Jahresspanne
104.46
157.27
Tagesänderung
-0.04%
Monatliche Änderung
+5.91%
6 month change
+7.82%
Jahresänderung
+21.41%
Vorheriger Schlusskurs
135.5 8
Open
135.4 1
Tief
134.5 8
High
136.4 8
Volumen
1 759
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 168.26 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Arzneimittelhersteller – allgemein
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
18.96
Preis-Umsatz-Verhältnis
5.88
Dividende je Aktie
0.82
Dividendenrendite in %
3.99

Gilead Sciences, Inc. - Common Stock

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

Nachrichten